Navigation Links
New Cancer Treatment Shrinks Pancreatic Tumor
Date:11/23/2008

NASHVILLE, Tenn., Nov. 24 /PRNewswire/ -- A new cancer treatment is realizing outstanding results against pancreatic cancer. Following five weeks of treatment, a patient's large, stage 4 tumor was reduced in size by 70%. After seven more weeks of treatment, it no longer could be definitely identified on scans. Pancreatic cancer usually is fatal six to nine months after diagnosis. NeoPlas Innovation's combination of FDA-approved drugs appears to improve those odds for some patients, based on this result and similar ones seen before the protocol's public availability.

The tumor reduction correlated with resolution of the patient's symptoms of pain and digestive problems. "The cancer isn't gone," emphasized NeoPlas Innovation Director of Research Dr. Stephen B. Cantrell. "There are still several metastatic lesions to address, but this kind of response is virtually unheard of in pancreatic cancer. At the very least, we're looking at his having many, many months of added survival with a quality of life he can truly enjoy."

The patient's daughter discussed her father's treatment, saying "He began the NeoPlas treatment after he became too ill to complete his final course of radiation following chemotherapy." She added, "Since then, he has been able to resume work two to three hours a day, go to lunch with other men and even take a ten-day trip to Europe with my brother."

The cholesterol drug Lovastatin is a key part of this treatment that has arrested or eradicated tumors in 78% of initial patients. The first person treated with the investigative protocol in 2000 had stage 4 melanoma; he remains disease-free today.

Based on experience and relevant lab research to date, staff members expect the best results for several malignancies. In addition to pancreatic cancer and melanoma, they include colon cancer, renal (kidney) cancer, mesothelioma, and a group of sarcomas, including osteosarcoma, chondrosarcoma and malignant fibrous histiocytoma.

Fatigue is the most notable side effect of NeoPlas Innovation's cancer treatment. Most patients never experience effects commonly affiliated with chemotherapy or radiation (nausea, vomiting, hair loss, bone marrow suppression or immune system suppression). An experienced physician prescribes and monitors the outpatient treatment.

A web site, http://www.neoplas.org, provides answers to common questions and a screening tool. Individuals can reach NeoPlas at 615-371-8100 or by e-mailing office@neoplas.org.

For an interview with Dr. Cantrell, call 615-371-8100 or e-mail office@neoplas.org.


'/>"/>
SOURCE NeoPlas Innovation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
2. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
3. Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test
4. PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies
5. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
6. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
7. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
8. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
9. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
10. SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
11. NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... FRANCISCO , Feb. 11, 2016   Health ... advancement of new health technologies, announced today " 10 ... achievements in health tech over the past ten years.   ... For nearly a decade, Health 2.0 has served as ... showcased and connected with thousands of technologies, companies, innovators, ...
(Date:2/11/2016)... AAIPharma Services Corp./Cambridge Major Laboratories, Inc. ... development services for the pharmaceutical and biotechnology industries, ... in its Charleston, SC ... recent investments. Charleston ... with small-scale lyophilization. The site has invested in ...
(Date:2/11/2016)... , 11 de fevereiro de 2016  A ... sua fábrica de soroalbumina bovina (BSA -- ... fábrica fica na Ilha Norte da Nova Zelândia, ... e estabelecido na fábrica da Proliant nos EUA, ... O projeto e instalação dos equipamentos foram feitos ...
Breaking Medicine Technology:
(Date:2/12/2016)... CITY, California (PRWEB) , ... February 12, 2016 , ... ... announce their participation in Red Carpet Events LA GRAMMY’s Style Lounge Event. Coco Libre ... healthy way to stay hydrated before the big event. The invitation-only gifting suite, held ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman ... John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, ... VA Southern Nevada Healthcare System. This will be the first Fisher House in ...
(Date:2/12/2016)... ... February 12, 2016 , ... Young ... area, celebrates the beginning of the latest charity campaign in their community enrichment ... art. Donations to this worthy cause are currently being accepted at: http://artexpressioninc.org/ ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mediaplanet today announces the ... print component of “Revolutionizing Cancer Care” is distributed within the February 12 issue ... with a circulation of approximately 250,000 copies and an estimated readership of 750,000 ...
(Date:2/12/2016)... ... February 12, 2016 , ... A lot has been reported ... A president has access to health and wellness resources most Americans could ever dream ... single individual has a schedule as frenetic as the U.S. President. , In ...
Breaking Medicine News(10 mins):